AllAnalyst Report
logoArgusFebruary 12, 2024

Vertex Pharmaceuticals Incorporated: Raising target price to $465

Symbols
VRTX
Sector(s)
Healthcare
Rating
Current Price
$397.48
Price Target
Earnings Estimate
Summary

Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 4,800 employees. It has research programs and facilities in

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

Jasper Hellweg

Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.